help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bassetti, M.
Right arrow Articles by Giannattasio, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bassetti, M.
Right arrow Articles by Giannattasio, G.

Journal of Clinical Endocrinology & Metabolism, Vol 58, 268-273, Copyright © 1984 by Endocrine Society

ARTICLES

Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study

M Bassetti, A Spada, G Pezzo and G Giannattasio

A morphological study was carried out on eight macroprolactinomas surgically removed from untreated patients and on nine macroprolactinomas removed from patients treated with bromocriptine (Brc; seven from patients treated for 6 weeks and two from patients treated for 1 yr). All treated patients had both serum PRL levels and tumor size (by computed tomographic scan) reduced. The study was carried out using light, immunofluorescence, and electron microscopic techniques and electron microscopic morphometry. By immunofluorescence microscopy, all tumors consisted of cells positive for PRL. In some treated tumors, the fluorescence was more marked than in untreated tumors. By light and electron microscopy and by morphometry, significant reductions in cell size were observed in the adenomas from Brc-treated patients. Both the cytoplasm and the nucleus shrank, but the reduction of the cytoplasm was much greater than that of the nucleus. The shrinkage of the cytoplasm was a consequence of marked involution of the rough endoplasmic reticulum and the Golgi complex in Brc-treated tumors. This effect may be related to inhibition of PRL synthesis by the drug. In some tumors from treated patients, the number of secretory granules was increased. No differences were observed between tumors from patients treated for 6 weeks and those from patients treated for 1 yr. The observed reduction in cell size by Brc could explain, at least in part, the well known size reduction of PRL- secreting adenomas in patients treated with the drug.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
V. Q. Passos, J. J. S. Souza, N. R. C. Musolino, and M. D. Bronstein
Long-Term Follow-Up of Prolactinomas: Normoprolactinemia after Bromocriptine Withdrawal
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3578 - 3582.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society